Protagonist Therapeutics Reports Mixed Quarterly Results with Revenue Growth and Rising Losses

**Protagonist Therapeutics, Inc.** (NASDAQ: PTGX) has released its quarterly results for the period ending March 31, 2025, highlighting both growth opportunities and challenges faced by the company. Below are key points extracted from their income statement and overall financial position:

Positive Aspects:

• **Revenue Growth:** License and collaboration revenue reached **$28.3 million**, notably due to the Takeda Collaboration Agreement and a recognition of a milestone payment associated with the VERIFY clinical trial.
• **Strong Cash Position:** As of March 31, 2025, the company reported **$697.9 million** in cash, cash equivalents, and marketable securities, up from **$559.2 million** a year ago.
• **Increased Interest Income:** Interest income surged **73%** to **$7.6 million** from **$4.4 million**, reflecting higher invested balances.
• **Controlled Operating Expenses:** Total operating expenses decreased slightly to **$47.6 million** from **$48.6 million**, indicating management's effort to control costs.

Negative Aspects:

• **Declining License Revenue:** A significant drop of **89%** in collaboration revenue compared to the previous year, primarily due to the recognition of a large upfront payment in 2024 under the Takeda agreement that inflated last year's figures.
• **Net Loss:** The company reported a net loss of **$11.7 million**, a stark contrast to a net income of **$207.3 million** in the prior year, primarily impacted by the decrease in revenue.
• **Increased Research and Development Expenses:** Expenses rose by **6%** to **$35.9 million**, driven by costs associated with ongoing clinical trials, particularly for rusfertide.
• **Deferred Revenue Decline:** Deferred revenue fell by **$5.5 million**, indicating fewer milestones achieved in the current period compared to the prior year.

Key Statistics:

• Three Months Revenue:** **$28.3 million** (vs. **$254.9 million** year-over-year)
• Operating Loss:** **$19.3 million** (compared to an operating income of **$206.3 million**)
• Net Loss Per Share:** **$(0.19)** (compared to a profit of **$3.41** in the prior year)
• Weighted Average Shares:** 62,963,806 (increased from 60,855,689 year-over-year)

In summary, while Protagonist Therapeutics shows promise with robust liquidity and growing interest income, it faces significant challenges with declining revenues and substantial operating losses. Continuous monitoring of milestones in their clinical trials will be crucial as they navigate through this period of transformation.